Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
Journal of Clinical Oncology · 10.01.2023 · 41 (2) · 212-221
DOI: 10.1200/jco.21.02961 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.01.2023. Verfasst von Paolo A Ascierto und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, I.N.T. IRCCS Fondazione "G. Pascale" Napoli, Naples, Italy. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Melanoma, Nivolumab, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 236-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Limited prospective data are available on sequential immunotherapy and BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma. METHODS SECOMBIT is a randomized, three-arm, noncomparative phase II trial (ClinicalTrials.gov identifier: NCT02631447 ). Patients with untreated, metastatic BRAFV600-mutant melanoma from 37 sites in nine countries were randomly assigned to arm A (encorafenib [450 mg orally once daily] plus binimetinib [45 mg orally twice daily] until progressive disease [PD] -> ipilimumab plus nivolumab [ipilimumab 3 mg/kg once every 3 weeks and nivolumab 1 mg/kg once every 3 weeks × four cycles -> nivolumab 3 mg/kg every 2 weeks]), arm B [ipilimumab plus nivolumab until PD -> encorafenib plus binimetinib], or arm C (encorafenib plus binimetinib for 8 weeks -> ipilimumab plus nivolumab until PD -> encorafenib plus binimetinib). The primary end point was overall survival (OS) at 2 years. Secondary end points included total progression-free survival, 3-year OS, best overall response rate, duration of response, and biomarkers in the intent-to-treat population. Safety was analyzed throughout sequential treatment in all participants who received at least one dose of study medication. RESULTS A total of 209 patients were randomly assigned (69 in arm A, 71 in arm B, and 69 in arm C). At a median follow-up of 32.2 (interquartile range, 27.9-41.6) months, median OS was not reached in any arm and more than 30 patients were alive in all arms. Assuming a null hypothesis of median OS of ≤ 15 months, the OS end point was met for all arms. The 2-year and 3-year OS rates were 65% (95% CI, 54 to 76) and 54% (95% CI, 41 to 67) in arm A, 73% (95% CI, 62 to 84) and 62% (95% CI, 48 to 76) in arm B, and 69% (95% CI, 59 to 80) and 60% (95% CI, 58 to 72) in arm C. No new safety signals emerged. CONCLUSION Sequential immunotherapy and targeted therapy provide clinically meaningful survival benefits for patients with BRAFV600-mutant melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, I.N.T. IRCCS Fondazione "G. Pascale" Napoli, Naples, Italy.
- Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy.
- University of Perugia, Perugia, Italy.
- Biotherapy of Tumors Unit, Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
- Immunotherapy and Cell Therapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska Curie National Research Institute of Oncology, Warsaw, Poland.
ORCID-Profile: Paolo A Ascierto, Mario Mandalà, Pier Francesso Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Ana Arance, Evaristo Maiello, Helen Gogas, Erika Richtig, Celeste Lebbè, Marco Tucci, Maria Gonzales Cao, Miguel F Sanmamed, Domenico Mallardo, Antonio M Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni
Zitieren
APA
Ascierto, P. A., Mandalà, M., Ferrucci, P. F., Guidoboni, M., Rutkowski, P., Ferraresi, V., Arance, A., Guida, M., Maiello, E., Gogas, H., Richtig, E., Fierro, M. T., Lebbè, C., Helgadottir, H., Queirolo, P., Spagnolo, F., Tucci, M., Del Vecchio, M., Gonzales Cao, M., …, & Chiarion Sileni, V. (2023). Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial. Journal of Clinical Oncology, 41(2), 212-221. https://doi.org/10.1200/jco.21.02961
Vancouver
Ascierto PA, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, et al. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial. Journal of Clinical Oncology. 2023;41(2):212-221. doi:10.1200/jco.21.02961
BibTeX
@article{Ascierto2023,
author = {Ascierto, Paolo A and Mandalà, Mario and Ferrucci, Pier Francesso and Guidoboni, Massimo and Rutkowski, Piotr and Ferraresi, Virginia and Arance, Ana and Guida, Michele and Maiello, Evaristo and Gogas, Helen and Richtig, Erika and Fierro, Maria Teresa and Lebbè, Celeste and Helgadottir, Hildur and Queirolo, Paola and Spagnolo, Francesco and Tucci, Marco and Del Vecchio, Michele and Gonzales Cao, Maria and Minisini, Alessandro Marco and De Placido, Sabino and Sanmamed, Miguel F and Mallardo, Domenico and Curvietto, Marcello and Melero, Ignacio and Palmieri, Giuseppe and Grimaldi, Antonio M and Giannarelli, Diana and Dummer, Reinhard and Chiarion Sileni, Vanna},
title = {Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {2},
pages = {212--221},
doi = {10.1200/jco.21.02961}
}
EUVIMED